- Home
- AGFY vs TOVX Comparison
AGFY vs TOVX Comparison
Compare AGFY & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGFY
- TOVX
- Stock Information
- Founded
- AGFY 2016
- TOVX 2001
- Country
- AGFY United States
- TOVX United States
- Employees
- AGFY N/A
- TOVX N/A
- Industry
- AGFY Military/Government/Technical
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- AGFY Consumer Discretionary
- TOVX Health Care
- Exchange
- AGFY Nasdaq
- TOVX Nasdaq
- Market Cap
- AGFY 3.8M
- TOVX 3.1M
- IPO Year
- AGFY 2021
- TOVX 2006
- Fundamental
- Price
- AGFY $0.24
- TOVX $4.35
- Analyst Decision
- AGFY
- TOVX
- Analyst Count
- AGFY 0
- TOVX 0
- Target Price
- AGFY N/A
- TOVX N/A
- AVG Volume (30 Days)
- AGFY 233.0K
- TOVX 1.8M
- Earning Date
- AGFY 08-14-2024
- TOVX 08-13-2024
- Dividend Yield
- AGFY N/A
- TOVX N/A
- EPS Growth
- AGFY N/A
- TOVX N/A
- EPS
- AGFY N/A
- TOVX N/A
- Revenue
- AGFY $11,590,000.00
- TOVX N/A
- Revenue This Year
- AGFY $468.67
- TOVX N/A
- Revenue Next Year
- AGFY N/A
- TOVX N/A
- P/E Ratio
- AGFY N/A
- TOVX N/A
- Revenue Growth
- AGFY N/A
- TOVX N/A
- 52 Week Low
- AGFY $0.23
- TOVX $2.75
- 52 Week High
- AGFY $3.54
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- AGFY 41.65
- TOVX 48.78
- Support Level
- AGFY $0.23
- TOVX $3.01
- Resistance Level
- AGFY $0.25
- TOVX $7.15
- Average True Range (ATR)
- AGFY 0.02
- TOVX 1.18
- MACD
- AGFY 0.00
- TOVX 0.09
- Stochastic Oscillator
- AGFY 41.22
- TOVX 36.36
About AGFY Agrify Corporation
Agrify Corp is a leading provider of innovative cultivation and extraction solutions for the cannabis industry, bringing data, science, and technology to the forefront of the market. Its proprietary micro-environment-controlled Agrify Vertical Farming Units (VFUs) enable cultivators to produce high-quality products The products offered by the company include Integrated Grow Racks, LED Grow Lights, Hydroponics, and Vertical Farming Units.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.